{"prompt": "['03', '04/04/2017', 'Third version - Further to ANSM request', 'Changes in duration: 6 weeks treatment and 6 weeks follow', 'up, inclusion criteria adapted: epistaxis>30 mn for 6 weeks.', 'Addition of blood samples at day 8 & 22 for tacrolimus', 'dosage. Addition of in vivo demonstration for ointment', 'administration.', '04', '21/06/2017', 'Fourth version', 'Further to the request of the independent monitoring and', 'safety committee, review of the rules for discontinuation of', 'the study in case of imbalance between the randomization', 'arms \u00a72.3.', 'Page 3 of 64']['CONTENTS', 'Synopsis', '9', 'The State of the Matter', '13', '1.1', 'Hereditary Hemorrhagic Telangiectasia (HHT)', '13', '1.1.1 Introduction', '13', '1.1.2', 'The disease', '13', '1.1.2.1', 'Clinical picture', '13', '1.1.2.2', 'Genetics and physiopathology', '14', '1.1.3', 'Nosebleeds', '14', '1.1.4', 'Treating nosebleeds in HHT', '15', '1.2', 'Angiogenesis and its regulation', '16', '1.2.1 Angiogenesis and HHT', '16', '1.3', 'Tacrolimus', '18', '1.3.1', 'Mechanism of action', '18', '1.3.2', 'Current indications', '19', '1.3.3', 'Safety: Ointment safety', '19', '1.3.3.1', 'Skin', '19', '1.3.3.2', 'Mucosae', '20', '1.3.3.3', 'Ophtalmic', '21', '1.3.4 Pharmacokinetic and systemic absorption', '21', '1.4', 'Tacrolimus and HHT', '21', '2', 'Justification for the study', '22', '2.1', 'Rationale for the study', '22', '2.2', 'Safety and rationale for the pharmaceutical form, means of administration and', 'doses used', '23', '2.3', 'Rationale for the methodology', '24', '3', 'Objectives', '27', '3.1', 'Main objective', '27', '3.2', 'Secondary objectives', '28', '4', 'Methodology', '28', '4.1', 'Outline of the experiment', '28', '4.1.1', 'Monitoring the patients', '28', '4.1.2', 'Patient selection', '28', '4.1.3', 'Duration of the study', '28', '4.2', 'Patients', '29', '4.2.1', 'Recruitment and feasibility', '29', '4.2.2', 'Number of patients', '29', '4.2.3', 'Modalities for recruitment, inclusion and follow-up', '30', '4.2.4', 'Inclusion criteria', '30', '4.2.5', 'Exclusion criteria', '30', '4.3', 'Assessment criteria for the study product', '31', '4.3.1 Main judgement criterion', '31', '4.3.2 Secondary judgement criteria', '31', '4.4', 'Randomization, blinding and lifting the blind', '32', '4.5', 'Modalities for premature termination of the treatment and withdrawal from the study', '33', '4.6', 'Rules for definitive termination', '33', '4.6.1 A research person terminates his or her participation in the study', '33', '4.6.2 Termination of all or part of the research', '33', '5', 'Description, supply and management of the drugs', '34', '5.1', 'General modalities of preparation and administration', '34', '5.2', 'Treatment tested', '34', '5.2.1 Modalities for the preparation', '34', '5.2.2', 'Storage and conservation', '34', '5.2.3', 'Return and destruction', '34', 'Page 4 of 64']['5.3', 'Placebo', '34', '5.3.1', 'Modalities for preparing', '34', '5.3.2 Storage and conservation of the placebo', '35', '5.3.3', 'Return and destruction', '35', '5.4', 'Associated treatments', '35', '5.5', 'Drug circuit', '35', '5.5.1', 'Supply', '35', '5.5.2 Dispensing the study products by the hospital pharmacy in the centers', 'participating in the study', '35', '5.6', 'Ointment tubes: presentation and supplier', '36', '6', 'Practical running of the study', '36', '6.1', 'General organization and study sites', '36', '6.2', 'Inclusion visit (V1)', '37', '6.2.1 Ointment administration', '38', '6.2.2 Recommendations', '38', '6.3', 'Phone calls on day 15, 14 days after the beginning of the treatment (up to day 18', 'tolerated)', '39', '6.4', 'Phone calls on day 31, 30 days after the beginning of the treatment (up to day 37', 'tolerated)', '39', '6.5', 'Visit at the end of the treatment, V2 = at day 43 (up to day 50 tolerated)', '40', '6.6', 'Visit after 6 weeks follow-up, V3 = at day 85 (up to day 100 tolerated)', '40', '6.7', 'Synopsis of the study per patient', '42', '7', 'Intercurrent events', '43', '7.1', 'Definitions', '43', '7.1.1', 'Adverse event', '43', '7.1.2', 'Serious adverse event (SAE)', '43', '7.1.3', 'Intensity', '43', '7.1.4', 'Adverse reaction', '44', '7.1.5 Reference document for the experimental drug', '44', '7.2', 'Responsabilities of the investigator', '44', '7.2.1', 'Adverse Events reporting', '44', '7.2.2 General AE/SAE reporting rules:', '44', '7.2.3', 'SAE declaration', '44', '7.2.4 Follow up of Adverse Events and Serious Adverse events', '45', '7.3', \"Sponsor's responsibilities\", '45', '7.4', 'Specific management of complications', '45', '7.4.1 Nosebleeds', '45', '7.4.2', 'Perforation of the nasal septum', '46', '7.4.3', 'Other complications associated with adverse events linked to topical tacrolimus', '46', '7.4.4 Tacrolimus systemic absorption', '46', '8', 'Data management', '46', '8.1', 'Electronic case report forms', '46', '8.2', 'Source documents', '47', '8.3', 'Archiving', '47', '8.4', 'Electronic data management', '47', '9', 'Statistics', '48', '9.1', 'Number of participants', '48', '9.2', 'Statistical analysis plan', '48', '9.2.1 Analysis populations', '48', '9.2.1.1 \"Efficacy\" population in intention to treat', '48', '9.2.1.2', '\"Efficacy\" population per protocol', '48', '9.2.1.3', '\"Safety\" population', '48', '9.2.2', 'Statistical methods', '49', '9.2.2.1', 'Populations', '49', '9.2.2.2', 'Deviation from the protocol', '49', 'Page 5 of 64']\n\n###\n\n", "completion": "END"}